Brilaroxazine
Clinical data | |
---|---|
Other names | RP5063; oxaripiprazole [1][2] |
Routes of administration | By mouth |
Drug class | Atypical antipsychotic |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >80% [3] |
Protein binding | >99% |
Metabolism | Liver (mostly via CYP3A4 (64%) and CYP2D6 (17%)) [4] |
Elimination half-life | 55 hours [3] |
Identifiers | |
| |
JSmol) | |
| |
|
Brilaroxazine (developmental code name RP5063), also known as oxaripiprazole,
Brilaroxazine is a third-generation antipsychotic and dopamine-serotonin system modulator due to its unique actions on dopamine and serotonin neurotransmitter systems compared to other antipsychotics.[9][10][11] Clinical data from phase I, phase II (NCT01490086), and phase III (NCT05184335) trials suggest that brilaroxazine may have favorable efficacy and a significantly improved side effect profile compared to existing third-generation drugs.[9][12][13]
Pharmacology
Pharmacodynamics
Brilaroxazine acts as a potent
Site | Ki (nM) | Action | |
---|---|---|---|
D1 |
100 | ND | |
D2 |
0.40 | Partial agonist | |
D2L |
0.45 | Partial agonist | |
D2S |
0.28 | Partial agonist | |
D3 |
3.7 | Partial agonist | |
D4 |
6.0 | Partial agonist | |
D5 |
200 | ND | |
5-HT1A | 1.5 | Partial agonist | |
5-HT2A | 2.5 | Weak partial agonist/ Antagonist | |
5-HT2B | 0.19 | Antagonist | |
5-HT2C | 39 | Antagonist | |
5-HT3 | 78 | ND | |
5-HT6 | 51 | Antagonist | |
5-HT7 | 2.7 | Antagonist | |
α4β2 nicotinic | 36.3 | ND | |
SERT | 107 | ND | |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. |
Chemistry
Brilaroxazine is identical to
Recent Developments
In October 2023, Reviva Pharmaceuticals released topline results from their pivotal RECOVER phase III clinical trial (NCT05184335). The RECOVER study was a 4-week, randomized, double-blind, placebo-controlled, multicenter trial where 411 patients received brilaroxazine 15 mg, 50 mg, or placebo once daily. The trial cohort consisted of 60% USA, 34% Indian, and 6% Bulgarian patients with balanced randomization and diverse demographic representation across all three trial arms. The primary endpoint was PANSS Total Score change from baseline vs placebo at week 4. Secondary endpoints were PANSS Positive Symptoms, PANSS Negative Symptoms, PANSS Negative Marder Factor, PANSS Social Cognition, PANSS Excitement/Agitation, CGI-S, and Personal and Social Performance (PSP) score changes from baseline vs placebo at week 4.
Brilaroxazine 50 mg successfully met all primary and secondary endpoints with statistically significant and clinically meaningful improvements over placebo across all major symptom domains. The primary endpoint PANSS Total Score change from baseline was -23.9 for brilaroxazine 50 mg vs -13.8 for placebo at week 4, resulting in a 10.1 point reduction over placebo (p < 0.001). Within the first week of dosing, brilaroxazine 50 mg already achieved separation from placebo in the primary endpoint and several secondary endpoints.
Endpoint | Point Reduction / Improvement | Cohen's d Effect Size | P Value |
---|---|---|---|
PANSS Total Score | 10.1 | 0.6 | <0.001 |
PANSS Positive Symptoms | 2.8 | 0.5 | <0.001 |
PANSS Negative Symptoms | 2.0 | 0.4 | 0.003 |
PANSS Negative Marder Factor | 2.1 | 0.4 | 0.002 |
PANSS Social Cognition | 1.6 | 0.5 | <0.001 |
PANSS Excitement/Agitation | 2.1 | 0.5 | <0.001 |
Personal and Social Performance (PSP) | 6.3 | 0.5 | <0.001 |
CGI-S | >= 1 | 0.5 | <0.001 |
The lower brilaroxazine 15 mg dose met two secondary endpoints at week 4, PANSS Social Cognition and Personal and Social Performance (PSP), and showed a clear improvement trend and increasing separation from placebo in the primary endpoint PANSS Total Score and PANSS Positive Symptoms score starting at week 3.
Brilaroxazine was very well tolerated and safe, with overall treatment emergent adverse event (TEAE) rates of 34.5% for brilaroxazine 15 mg, 35.5% for 50 mg, and 30% for placebo. Discontinuation rates for brilaroxazine were lower than for placebo and were 19% for brilaroxazine 15 mg, 16% for 50 mg, and 22% for placebo. Discontinuation rates due to drug side effects were also lower for brilaroxazine than for placebo and were 1% for brilaroxazine 15 mg, 0% for 50 mg, and 4% for placebo. Common TEAEs (>5%) were headache (<6%) and somnolence (<=7.5%) but these were mild-to-moderate in severity and generally transient in nature. There were no incidences of suicidal ideation.
There was no significant change in bodyweight, blood glucose, lipids, prolactin, or thyroid hormones compared to placebo. The percentage of patients who gained weight during the trial was 2.1% for brilaroxazine 15 mg, 5.9% for 50 mg, and 2.9% for placebo. This is a significant improvement over the currently prescribed third-generation antipsychotics aripiprazole (Abilify), brexpiprazole (Rexulti), and cariprazine (Vraylar). In comparable short-term (4-6 week) acute schizophrenia clinical trials, the percentage of patients taking a third-generation antipsychotic that had clinically relevant weight gain (>= 7% gain) was 9.2% for aripiprazole vs 4.3% for placebo, 10.4% for brexpiprazole vs 4.1% for placebo, and 9.2% for cariprazine vs 4.7% for placebo.[16][17] The meta-analysis studies used pooled data from each drug's entire schizophrenia dose range, therefore the results for the highest 50 mg dose of brilaroxazine would likely show even more significant improvement in weight change against comparable highest dosages of third-generation antipsychotics if the breakdown were available.
Reviva also has an ongoing 52-week, single-arm, phase III open-label extension (OLE) study of stable schizophrenia patients to further evaluate the long-term safety and tolerability of brilaroxazine as part of the RECOVER program (NCT05184335). In this study, rollover patients from the RECOVER 4-week double-blind trial as well as de novo stable schizophrenia patients receive brilaroxazine in a 15-30-50 mg flexible dosing schedule. Completion is expected in Q4 2024. In Q1 2024 Reviva plans to initiate RECOVER-2 in Q2 2024. RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 2025. If successful, commercial availability is anticipated by 2026.
See also
References
- ^ PMID 29767995.
- ^ ISBN 9781440839276.
- ^ a b c d "Reviva Corporate Presentation". Reviva Pharmaceuticals. Retrieved 2023-07-19.
- PMID 29619682.
- ^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. p. 20. Retrieved 2015-05-19.
- S2CID 42729570.
- S2CID 8513976.
- ^ "Reviva Product Pipeline". Reviva Pharmaceuticals. Retrieved 2023-07-19.
- ^ S2CID 19499381.
- ^ S2CID 13047310.
- ^ a b c d Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat (2013). "Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder" (PDF). American Society of Clinical Psychopharmacology. Retrieved 2015-05-19.
{{cite web}}
: CS1 maint: multiple names: authors list (link) - PMID 29637739.
- ^ "Reviva RECOVER Phase III Trial Topline Results" (PDF). Reviva Pharmaceuticals. Retrieved 2023-11-02.
- PMID 31339684.
- S2CID 256840074.
- PMID 29878915.
- PMID 28692485.